1. Introduction {#sec1-toxins-08-00233}
===============

*Pasteurella multocida* toxin (PMT) is the major virulence factor responsible for atrophic rhinitis, pasteurellosis, and dermonecrosis caused by infection with toxigenic capsular type D and some A strains of *Pasteurella multocida* (reviewed in \[[@B1-toxins-08-00233]\]). PMT is a 1285-amino acid AB protein toxin that acts intracellularly by gaining entry into host cells via binding membrane phospholipids phosphatidylcholine, sphingomyelin, and an as-yet unknown trypsin-sensitive protein partner \[[@B2-toxins-08-00233]\]. PMT is subsequently endocytosed and released from the late endosomes into the cytosol in a pH dependent manner \[[@B3-toxins-08-00233],[@B4-toxins-08-00233],[@B5-toxins-08-00233]\], where it targets heterotrimeric G-proteins and modulates their downstream signaling pathways (reviewed in \[[@B6-toxins-08-00233]\]). PMT acts on α subunits of the Gα~q/11~, Gα~12/13~, and Gα*~i~*~1/2/3~, but not Gα~s~ families \[[@B7-toxins-08-00233],[@B8-toxins-08-00233],[@B9-toxins-08-00233],[@B10-toxins-08-00233]\] through deamidation of a specific Gln residue in the switch II region of the active site of Gα subunits \[[@B11-toxins-08-00233]\], changing Glu to Gln and converting the Gα-protein into a constitutively active form.

Physiologically, PMT stimulates phospholipase C β-1 (PLCβ1) signaling through its preferential activation of Gα~q~ of the Gα~q/11~ family of G-proteins \[[@B9-toxins-08-00233],[@B10-toxins-08-00233]\]. By doing so, PMT increases the intracellular cytoplasmic concentration of Ca^2+^ and activates mitogenic signaling pathways, leading to increased cellular proliferation and in some cell types cell differentiation \[[@B9-toxins-08-00233],[@B12-toxins-08-00233]\]. PMT also indirectly activates Rho signal transduction through its action on Gα~q/11~ and Gα~12/13~ \[[@B13-toxins-08-00233],[@B14-toxins-08-00233],[@B15-toxins-08-00233],[@B16-toxins-08-00233]\], leading to actin cytoskeletal rearrangements and changes in cellular morphology \[[@B10-toxins-08-00233],[@B14-toxins-08-00233],[@B17-toxins-08-00233],[@B18-toxins-08-00233],[@B19-toxins-08-00233],[@B20-toxins-08-00233],[@B21-toxins-08-00233]\]. Thus far, the only Gα subunit that PMT does not deamidate or activate is Gα~s~ \[[@B8-toxins-08-00233],[@B22-toxins-08-00233],[@B23-toxins-08-00233]\], the stimulatory regulator of adenylate cyclase (AC). Instead, PMT inhibits adenylate cyclase activity through its activation of inhibitory AC regulators of the Gα*~i~* family \[[@B23-toxins-08-00233]\]. PMT activation of these different G-protein signaling pathways, in conjunction with crosstalk among the downstream signaling pathways, can lead to multiple cellular outcomes (reviewed in \[[@B6-toxins-08-00233],[@B24-toxins-08-00233]\]).

Although PMT modulates numerous intracellular signaling pathways to dictate cellular fate by constitutive activation of the Gα proteins, the overall activation of downstream signaling is not sustained and is subsequently mitigated by an unknown mechanism of downregulation. PMT causes an initial strong activation of downstream calcium and mitogenic signaling, which is subsequently followed by an uncoupling of the signaling in the case of Gα~q-~CPLCβ1 \[[@B9-toxins-08-00233],[@B21-toxins-08-00233]\] and Gα*~i~*~-~AC \[[@B23-toxins-08-00233]\]. Moreover, it has been shown that prolonged PMT treatment is sufficient to downregulate Gα~q~-mediated G-protein-coupled inward rectifying K^+^ channels \[[@B25-toxins-08-00233],[@B26-toxins-08-00233],[@B27-toxins-08-00233]\] and to block agonist-induced binding of GTPγS binding to Gα*~i~* protein \[[@B23-toxins-08-00233]\].

It is well established that sustained exposure of many G-protein-coupled receptors (GPCR), including those coupled with G~q~ and G~11~ proteins, to their cognate agonist results in desensitization of the pathway due to a sequestration, modification or reduction in cellular levels of the receptor and/or the Gα subunit \[[@B28-toxins-08-00233],[@B29-toxins-08-00233],[@B30-toxins-08-00233],[@B31-toxins-08-00233],[@B32-toxins-08-00233],[@B33-toxins-08-00233],[@B34-toxins-08-00233]\]. This desensitization or downregulation may also result from a redistribution of the Gα proteins in the membrane to the cytosol, or within membranes from detergent resistant membranes (DRMs, or lipid rafts) to more soluble membrane fractions \[[@B34-toxins-08-00233],[@B35-toxins-08-00233],[@B36-toxins-08-00233],[@B37-toxins-08-00233],[@B38-toxins-08-00233]\]. Indeed, some GPCRs, G proteins, and their effectors are not only localized in DRMs, but also dynamically move in and out of them during signal transduction \[[@B39-toxins-08-00233]\]. In each of these cases, the downregulation of Gα signaling was mediated through agonist binding of the GPCR. Until now, discerning how the subsequent cellular downregulation of PMT-modified Gα-proteins occurs has not been studied.

In this study, we investigated the fate of the Gα~q~, Gα~11~, and Gα~s~ proteins in HEK-293T cells after PMT treatment by determining the levels of the Gα protein in whole cell lysates, total membranes, detergent resistant membranes (DRMs), and the soluble membrane and cytosolic fractions. Results from our experiments indicate that treatment of HEK-293T cells with wildtype PMT, but not catalytically inactive mutant PMT (C1165S), stimulates the selective downregulation of Gα~q~, but not Gα~s~ or Gα~11~, through redistribution of the Gα~q~ protein from DRMs to soluble membrane and cytosolic fractions with overall loss of Gα~q~ protein from the plasma membrane.

2. Results {#sec2-toxins-08-00233}
==========

2.1. The Cytotoxic Effect of PMT on Cultured HEK-293T Cells {#sec2dot1-toxins-08-00233}
-----------------------------------------------------------

Recombinant, full-length PMT induced morphological effects in cultured HEK-293T cells, similar to that previously described for other cells \[[@B21-toxins-08-00233]\]. PMT caused dosed-dependent rounding up and clumping of cells, as shown in [Figure 1](#toxins-08-00233-f001){ref-type="fig"}, and reorganization of the actin cytoskeleton (data not shown). Similar treatment with *N*-terminal (residues 1--506) or *C*-terminal (residues 486--1285) PMT fragments had no effect on cell morphology (data not shown).

2.2. PMT Treatment Reduces Endogenous Gα~q/11~ Levels in Detergent Resistant Membranes (DRMs) {#sec2dot2-toxins-08-00233}
---------------------------------------------------------------------------------------------

Because PMT acts directly on its Gα substrates and subsequent modulation of signaling is independent of agonist-receptor coupling to the G protein \[[@B9-toxins-08-00233],[@B40-toxins-08-00233],[@B41-toxins-08-00233]\], we considered two possible mechanisms for PMT-mediated down-regulation of Gα~q/11~-PLCβ1 signaling: (1) PMT deamidation and activation of Gα~q~ and/or Gα~11~ leads to degradation of the resulting constitutively active Gα subunit and loss of cellular levels of Gα~q~ and/or Gα~11~; or (2) PMT deamidation and activation of Gα~q~ and/or Gα~11~ leads to redistribution of the resulting constitutively active Gα subunit from DRMs to soluble membrane and/or cytosolic fractions. In agreement with a previous report \[[@B42-toxins-08-00233]\], immunoblot analysis of total cell lysates using antibodies against the *C*-terminus of Gα~q/11~ showed that overnight treatment of the cells with PMT did not alter endogenous protein levels of Gα~q/11~ in total cell lysates ([Figure 2](#toxins-08-00233-f002){ref-type="fig"}). This result did not support the first proposed mechanism for PMT-mediated downregulation of Gα~q/11~ signaling, and so we next considered the second possibility that the downregulation of signaling might result from loss of the PMT-activated Gα~q/11~ from the membrane. Thus, we examined whether PMT treatment could cause loss of Gα~q/11~ protein from detergent-resistant membranes (DRMs, also called lipid rafts) since many membrane signaling molecules are enriched in these membrane micro-domains.

PMT-treated HEK-293T cells were lysed in the presence of detergent and the cellular contents were subjected to subcellular fractionation by separation using Optiprep density gradient centrifugation, followed by immunoblotting analysis of the gradient fractions. In the density gradient centrifugation profile, fractions \#1--7 contain low-density lipid-rich membranes and vesicles, while fractions \#8--12 contain high-density protein-rich soluble membrane and cytosolic fractions \[[@B43-toxins-08-00233]\]. As shown in [Figure 2](#toxins-08-00233-f002){ref-type="fig"}, whereas the abundant Gβ and Gα~s~ subunits were found throughout the gradient in both higher density (\#8--12) and lower density fractions (\#4--7) from untreated control cells, the majority of the less abundant Gα~q/11~ subunits were localized mostly to the low-density, DRM-containing fraction (\#5), as evidenced by its co-localization with flotillin-1, a known specific marker for DRMs \[[@B44-toxins-08-00233]\]. In contrast, PMT treatment resulted in the depletion of Gα~q/11~, but not Gβ or Gα~s~, from the DRM-containing fraction \#5. With this loss was a concomitant increase of Gα~q/11~ in the soluble membrane and cytosolic fractions (\#8--12), suggesting that PMT modification and activation of Gα~q/11~ results in the release of active form of the Gα~q/11~ protein from DRMs. That PMT treatment did not significantly alter the levels of Gα~s~ or Gβ in DRMs, as compared with flotillin-1, confirms previous findings, indicating that Gα~s~ protein is not a target substrate of PMT.

A time course revealed that while overall endogenous Gα~q/11~ protein levels in cells were not discernably affected by exposure to PMT over 12 h, the Gα~q/11~ levels in DRMs were reduced by over 80% by 8--10 h in cells treated with 0.3 nM PMT ([Figure 3](#toxins-08-00233-f003){ref-type="fig"}a). This result supports the notion that PMT action on Gα~q/11~ causes a redistribution of the protein, and not degradation within this timeframe. By 12 h, however, the Gα~q/11~ levels in DRMs were restored to nearly 80% that of untreated cells. Again, Gβ and flotillin levels remained unaffected by PMT treatment. The decrease in Gα~q/11~ levels in DRMs was also dose-dependent, exhibiting an EC~50~ value of \~70 pM ([Figure 3](#toxins-08-00233-f003){ref-type="fig"}b). Although the loss of Gα~q/11~ from DRMs was about 65% and 75% after 10 h of PMT treatment at a concentration of 320 pM and 650 pM, respectively, the Gα~q/11~ levels were again restored at higher PMT concentrations of 1.3 nM. Similar results were obtained using Swiss 3T3 cells (data not shown). Taken together, PMT selectively induces the loss of Gα~q/11~ proteins from DRMs in a time and dose dependent manner, although this loss can be masked or overcome at later times or higher toxin concentrations by PMT-stimulation of new protein synthesis.

2.3. PMT Treatment Depletes Gα~q~, but Not Gα~11~, Protein Levels in DRMs and the Plasma Membrane {#sec2dot3-toxins-08-00233}
-------------------------------------------------------------------------------------------------

To distinguish the specificity of the PMT-mediated DRM depletion for Gα~q~ and Gα~11~, we expressed exogenously either Gα~q~ or Gα~11~ in HEK-293T cells over the endogenous background and detected the proteins using the anti-Gα~q/11~ antibodies under conditions where the corresponding endogenous proteins were negligible ([Figure 4](#toxins-08-00233-f004){ref-type="fig"}a). The transfected cells overexpressing Gα~q~ or Gα~11~ were then used to determine the effect of PMT treatment on the DRM levels of overexpressed Gα~q~ or Gα~11~ proteins vs. Gβ. Results of immunoblot analysis of the DRM-containing fractions from a time course of treatment with 1.2 nM PMT revealed that PMT treatment caused a transient DRM depletion of Gα~q~ ([Figure 4](#toxins-08-00233-f004){ref-type="fig"}b) but not Gα~11~ ([Figure 4](#toxins-08-00233-f004){ref-type="fig"}c) after 2 h treatment.

Considering that PMT selectively depletes Gα~q~ and not Gα~11~, we considered the possibility that one reason we did not observe discernable depletion of endogenous Gα~q~ protein levels from total cell lysates ([Figure 2](#toxins-08-00233-f002){ref-type="fig"} and [Figure 3](#toxins-08-00233-f003){ref-type="fig"}) might be due to masking by the remaining Gα~11~ present in the membranes, as well as by the replacement with newly synthesized protein. We thus investigated the effect of PMT on Gα~q~ and Gα~11~ levels in total membrane preparations from cells selectively overexpressing each of the proteins. As shown in [Figure 5](#toxins-08-00233-f005){ref-type="fig"}, PMT treatment caused a dose- and time-dependent reduction of Gα~q~, but not Gα~11~, protein levels in total membrane preparations from cells overexpressing the respective Gα protein. In contrast, PMT treatment of cells overexpressing Gα~11~ resulted in a slight increase in overall Gα~11~ protein levels in membranes. However, unlike the case for DRMs, the loss of Gα~q~ from membranes did not recover over the 8 h treatment period.

To further discern specificity for PMT-modified Gα~q~ and not Gα~11~ as preferred target for membrane depletion, we transiently overexpressed FLAG-tagged Gα~q~ or FLAG-tagged Gα~11~ separately in HEK-293T cells and investigated the effect of PMT on the corresponding protein levels in DRMs. Results shown in [Figure 6](#toxins-08-00233-f006){ref-type="fig"} are similar to those obtained in [Figure 4](#toxins-08-00233-f004){ref-type="fig"}. PMT caused a dose- and time-dependent depletion of FLAG-Gα~q~ but not FLAG-Gα~11~ from DRMs. Again the effect was transient with FLAG-Gα~q~ levels recovering by 6--8 h ([Figure 6](#toxins-08-00233-f006){ref-type="fig"}c). Also consistent with data in [Figure 4](#toxins-08-00233-f004){ref-type="fig"}, cells overexpressing FLAG-Gα~11~ showed no PMT-mediated loss of the protein in DRMs, and instead the protein levels increased slightly ([Figure 6](#toxins-08-00233-f006){ref-type="fig"}c).

2.4. The Catalytic Activity of PMT Is Required for Membrane Depletion of Gα~q~ {#sec2dot4-toxins-08-00233}
------------------------------------------------------------------------------

Since PMT specifically induces the depletion of only Gα~q~ from the membrane even though Gα~11~ is also apparently a substrate for deamidation, we wanted to test if the deamidase activity of PMT is required for the depletion of Gα~q~ from the membrane. The catalytic domain of PMT possesses a cysteine-histidine-aspartic acid catalytic triad in the active site, where mutation of the cysteine residue into serine (PMT C1165S) reduces the enzymatic deamidase activity by 1000-fold \[[@B45-toxins-08-00233]\]. As shown in [Figure 7](#toxins-08-00233-f007){ref-type="fig"}, treatment of cells with PMT C1165S does not result in membrane depletion of Gα~q~, and neither PMT nor PMT C1165S caused the depletion of Gα~11~, confirming that the enzymatic activity of PMT is necessary for the depletion of Gα~q~ from the host cell membrane.

2.5. Overexpression of the Constitutively Active Forms of Gα~q~ Alone nor in the Presence of PMT Is Sufficient to Induce Its Depletion from the Plasma Membrane {#sec2dot5-toxins-08-00233}
---------------------------------------------------------------------------------------------------------------------------------------------------------------

Since the catalytic activity of PMT is required for the depletion of Gα~q~ from total membrane samples, and the consequence of PMT action renders the G-proteins constitutively active, we wanted to explore whether or not constitutive activity of Gα~q~ alone was sufficient to induce the depletion or exclusion of the activated Gα~q~ protein from the plasma membrane. We transfected HEK-293T cells separately with Gα~q~, Gα~11~, and their corresponding constitutively active mutants, with known dominant-active mutations, Gα~q~ Q209L and Gα~11~ Q209L, and with mutations equivalent to that introduced by PMT action, Gα~q~ Q209E and Gα~11~ Q209E ([Figure 8](#toxins-08-00233-f008){ref-type="fig"}a). First, we tested if overexpressing constitutively active Gα-proteins in HEK-293T cells causes similar cytotoxic morphological effects as PMT treatment. Exogenous expression of Gα~q~ or Gα~11~ caused little effect on morphology after 24 h, but, as expected, overexpression of each of the four constitutively active mutants of Gα~q~ or Gα~11~ results in the rounding up and clumping of cells, similar to that caused by PMT treatment ([Figure 8](#toxins-08-00233-f008){ref-type="fig"}b).

Unlike with the case of exogenous expression of Gα~q~ protein, PMT treatment had no affect on the localization of the exogenously expressed constitutively active Gα~q~ Q209E or Gα~q~ Q209L mutant proteins in membranes ([Figure 8](#toxins-08-00233-f008){ref-type="fig"}c), suggesting that the presence of the activated form of the Gα~q~ protein alone is not sufficient to cause its removal from the plasma membrane by PMT.

3. Discussion {#sec3-toxins-08-00233}
=============

We previously showed that microinjection of PMT into voltage-clamped *Xenopus* oocytes invoked a rapid (within 10 s) Ca^2+^-dependent Cl^−^ current, which involved activation of Gα~q/11~-PLCβ1 \[[@B9-toxins-08-00233]\]. In this previous study, the response to PMT was transient, such that the initial strong response was followed by subsequent downregulation and unresponsiveness to further stimulation by PMT. A similar initial activation and subsequent downregulation of PMT-stimulated Ca^2+^ and mitogenic signaling was evidenced in mammalian cells through studies involving cell cycle analysis \[[@B21-toxins-08-00233],[@B46-toxins-08-00233]\]. This downregulation of G~q~ signaling by PMT was reminiscent of receptor-mediated downregulation of G~q~-protein signaling that occurs upon prolonged exposure to agonist \[[@B34-toxins-08-00233],[@B35-toxins-08-00233],[@B36-toxins-08-00233],[@B37-toxins-08-00233],[@B38-toxins-08-00233]\], specifically the shift of Gα~q~ proteins from DRMs to soluble membrane fractions or the cytosol during agonist-stimulated signal transduction \[[@B39-toxins-08-00233]\]. This prompted us to explore the possibility that PMT-mediated activation of its Gα substrates, Gα~q~ and/or Gα~11~, results in a similar uncoupling of the corresponding G-protein-signaling pathway.

We considered the possibility that although PMT might have little or no effect on total cellular content of Gα~q/11~ proteins, PMT deamidation and subsequent activation of the Gα~q/11~ proteins may cause downregulation of G~q/11~ signaling through depletion of Gα~q/11~ levels in DRMs. The results presented here show for the first time that PMT induces both dose- and time-dependent depletion of Gα~q~ but not Gα~11~ from membrane lipid rafts in HEK-293T cells with concomitant shift of Gα~q~ to soluble membrane fractions or cytosol. Indeed, there was no significant decrease in Gα~q~ or Gα~11~ observed for any of the time points in the control experiments with no PMT treatment or for the Gα~11~ protein in the PMT-treated experiments; a transient decrease in Gα~q~ protein levels was observed only in PMT-treated cells. We further showed that this PMT-induced depletion occurs within DRM fractions from cells expressing endogenous levels of Gα~q/11~ proteins, as well as whole membranes and DRM fractions from cells overexpressing wildtype Gα~q~, and in DRM fractions from cells overexpressing FLAG-tagged Gα~q~, but not Gα~11~ proteins. Moreover, this PMT-mediated membrane redistribution of Gα~q~ was dependent on the deamidase activity of PMT since a catalytic mutant PMT C1165S did not cause membrane depletion of Gα~q~.

Specifically, when cellular contents of PMT treated cells were separated into fractions by OptiPrep or sucrose density gradient centrifugation, we found that PMT treatment resulted in the loss of Gα~q~ subunit from the flotillin-1-enriched DRM-containing fraction \#5 with a concomitant increase of Gα~q~ protein in the more soluble fractions (\#8--12) of the gradient. The effect of PMT was specific for Gα~q~, and not for other Gα subunits that are not targets of PMT, such as Gα~s~ or Gβ. Moreover, PMT-treatment caused membrane depletion of Gα~q~ and not Gα~11~. Gα~q~ and Gα~11~ share very similar structural homology and sequence identity of over 90%, and Gα~11~ can also be deamidated by PMT in cells \[[@B7-toxins-08-00233],[@B8-toxins-08-00233]\]. The sensitive commercially available antibody that we used in this study to detect endogenous protein levels recognizes the *C*-terminus of both Gα~q~ and Gα~11~. Thus, to distinguish the specificity of the PMT-mediated DRM and membrane depletion for Gα~q~ vs. Gα~11~, we decided to use an overexpression approach, where we exogenously expressed either Gα~q~ or Gα~11~ and detected the proteins using the anti-Gα~q/11~ antibodies. Under these conditions, endogenous levels of Gα~q~ and Gα~11~ were not detectable in the resulting immunoblots.

The finding that the continued exposure to PMT was neither able to sustain the loss of nor perpetuate further loss of Gα~q~ from DRMs suggests that the cellular Gα~q~ levels in DRMs are replenished as a result of increased Gα~q~ protein synthesis. Previous studies have shown that PMT induces protein synthesis and cellular proliferation in a cycloheximide-sensitive manner \[[@B47-toxins-08-00233],[@B48-toxins-08-00233]\]. This notion is supported by the slight increase (not decrease) observed for Gα~11~ under similar conditions. Alternatively, it is possible that the observed replenishment of Gα~q~ in the DRMs may also be due to a redistribution of the preexisting or newly synthesized monomeric Gα~q~ protein that is in the membrane. However, unlike in the case for DRMs, the loss of Gα~q~ from total membranes did not appear to replenish with time, suggesting that PMT modification and activation of Gα~q~ uncouples the signaling pathway in such a way as to interfere with the ability of newly synthesized Gα~q~ to interact with membranes, presumably through preventing reassociation with Gβγ subunits and coupling to GCPRs. The relatively faster response times for depletion and replenishment of the exogenously expressed Gα~q~ protein, compared to that observed for endogenous protein, was presumably due to the increased levels of Gα~q~ protein available as a substrate for PMT and saturation of the signaling system from enhanced protein synthesis of Gα~q~ encoded by the expression plasmid. Further, this PMT-mediated loss of Gα~q~ from DRMs and membranes is apparently masked at the total cell level (whole cell lysates) through redistribution to soluble membrane fractions or cytosol, as evidenced from the results shown in [Figure 2](#toxins-08-00233-f002){ref-type="fig"} and [Figure 3](#toxins-08-00233-f003){ref-type="fig"}, and through synthesis of new Gα~q~ protein, which counters the overall PMT-mediated loss of Gα~q~ protein from membranes.

Since overexpression of Gα~q~ Q209E or Gα~q~ Q209L in HEK-293T cells resulted in similar morphological effects as PMT treatment, we explored whether exogenous expression of these constitutively active mutants would lead to their localization in the membrane and DRMs or would also result in their membrane depletion. Since we found that the presence of constitutively active Gα~q~ mutant proteins alone was not sufficient to induce their depletion or exclusion from membranes, we next considered whether PMT treatment could induce the removal of pre-existing constitutively active Gα~q~ from the cell plasma membrane. However, we found that PMT treatment had no effect on the membrane localization of exogenously expressed constitutively active Gα~q~ mutant proteins.

Although the antibodies we used could not distinguish whether only the deamidated form of the Gα~q~ is depleted from DRMs, our results clearly indicate the PMT catalytic activity is required. If PMT-mediated deamidation is required for depletion, and both Gα~q~ and Gα~11~ can serve as substrates for deamidation by PMT \[[@B8-toxins-08-00233]\], then PMT-deamidated Gα~11~ should also be depleted from DRMs. However, our results ([Figure 4](#toxins-08-00233-f004){ref-type="fig"}c) indicate that this is not the case. This suggests that either cellular Gα~11~ is a very poor substrate for PMT and does not get deamidated to any significant extent during the time studied or that the as-yet-undefined factor(s) responsible for depletion do not recognize the PMT-deamidated Gα~11~ as they do the PMT-deamidated Gα~q~. These possibilities might be explored further under endogenous conditions by using antibodies that distinguish Gα~q~ from Gα~11~ coupled with those that recognize the deamidated forms of the Gα proteins, such as those previously reported \[[@B7-toxins-08-00233],[@B8-toxins-08-00233]\].

These results suggest that PMT does not directly deplete the modified Gα~q~ protein from the membrane, but PMT might indirectly activate an unknown cellular component at the membrane or expedite a cellular process responsible for the downregulation of membrane-associated PMT-modified Gα~q~. This further suggests that the depletion mechanism of PMT-modified Gα~q~ proteins from the membrane has specificity and that PMT-catalyzed deamidation and activation of the Gα~q~ protein is the not the sole signal for initiating the downregulation process. Whether similar membrane depletion occurs for other Gα substrates of PMT once they are deamidated and activated remains to be determined.

4. Materials and Methods {#sec4-toxins-08-00233}
========================

4.1. Materials {#sec4dot1-toxins-08-00233}
--------------

Human embryonic kidney 293-T (HEK-293T) cells were obtained from the American Type Culture Collection (ATCC\# CRL-3216). Goat polyclonal antibodies against Gα~s~ (A-16, sc-26766), mouse monoclonal antibody against β tubulin (D-10, sc-5274), rabbit polyclonal antibodies against Gα~q~/~11~ (C-19, cat\# sc-392), Gβ (T-20, sc-378) and flotillin-1 (H-104, sc-25506), as well as horseradish peroxidase-conjugated donkey anti-goat IgG (sc-2020), goat anti-rabbit IgG (sc-2004), and goat anti-mouse IgG (sc-2005) antibodies, were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Mouse monoclonal anti-FLAG antibody (M2, F3165) and mammalian protease inhibitor cocktail was purchased from Sigma (St. Louis, MO, USA). All cell culture reagents were purchased from Life Technologies (Thermo Fisher Scientific, Grand Island, NY, USA). Restriction enzymes and other molecular biology reagents were obtained from Roche Biochemicals (Sigma-Aldrich, St. Louis, MO, USA) or New England Biolabs (Ipswich, MA, USA). OptiPrep was obtained from Axis-Shield PoCAS (Dundee, Scotland, UK). SuperSignal West Pico Chemiluminescent Substrate was purchased from Pierce Biotechnology (Thermo Fisher Scientific, Grand Island, NY, USA). Bio-Rad protein assay dye reagent was purchased from Bio-Rad Laboratories (Hercules, CA, USA). Full-length recombinant PMT and catalytically inactive mutant PMT C1165S were cloned, expressed, purified, quantified, and assayed for biological activity, as previously described \[[@B4-toxins-08-00233],[@B21-toxins-08-00233],[@B46-toxins-08-00233]\].

4.2. Mammalian Expression Vectors Encoding Gα Proteins {#sec4dot2-toxins-08-00233}
------------------------------------------------------

DNA encoding human Gα~q~, Gα~11~, Gα~q~ Q209L, and Gα~11~ Q209L genes (GB ACC\# U43083; UMR cDNA Resource Center) \[[@B49-toxins-08-00233]\] was cloned into the KpnI/XhoI sites of pcDNA3.1^+^ (Invitrogen, Thermo Fisher Scientific, Grand Island, NY, USA). For immunoblot detection, a FLAG-tag flanked at each end by a 6-residue linker sequence (SGGGGS) was introduced between residues 121 and 122 of Gα~q~ and Gα~11~ by using the following primers: Gα~q~F1: 5′-GCTT[GGTACC]{.ul}ACCATGACTCTGGAGTCCAT-3′Gα~q~R1: 5′-GA[GATATC]{.ul}CGCCGCCGCCAGACACCTTCCCACATCAAC-3′Gα~q~F4: 5′-GA[GATATC]{.ul}CCGATACAAAGACGATGACGACAAGGGCGGAGGCGGC-3′Gα~q~F5: 5′-GACGACAAGGGCGGAGGCGGCTCTGCTTTTGAGAATCCATATGTAG-3′Gα~q~R2: 5′-GA[CTCGAG]{.ul}TTAGACCAGATTGTACTC-3′Gα~11~F1: 5′-GCTT[GGTACC]{.ul}ACCATGACTCTGGAGTC-3′Gα~11~R1: 5′-GA[GATAT]{.ul}CCGCCGCCGCCGGACACCTTCTCCACGTCCAC-3′Gα~11~F3: 5′-GACGACAAGGGCGGAGGCGGCTCTACCTTCGAGCATCAGTACGTC-3′Gα~11~R2: 5′-CTAGA[CTCGAG]{.ul}TCAGACCAGGTTGTAC-3′

(KpnI, EcoRV and XhoI restriction enzyme sites are underlined). All subcloning procedures were confirmed by using restriction enzyme and DNA sequencing analysis. Generation of the Q209E mutants of Gα~q~ and Gα~11~ was completed by PCR cloning using the following primers: Gα~q~F1: 5′-CGATGTAGGCGGCGAAAGGTC-3′Gα~q~R1: 5′-GACCTTTCGCCGCCTACATCG-3′Gα~q~F2: 5′-TGTCGTAACAACTCCGCCCCA-3′Gα~q~R2: 5′-ACACCTACTCAGACAATGCGATGCA-3′Gα~11~F1: 5′-GTGGGCGGCGAGCGGTCGG-3′Gα~11~R1: 5′-CCGACCGCTCGCCGCCCAC-3′Gα~11~F2: 5′-TGTCGTAACAACTCCGCCCCA-3′Gα~11~R2: 5′-ACACCTACTCAGACAATGCGATGCA-3′

4.3. Transient Transfection {#sec4dot3-toxins-08-00233}
---------------------------

HEK-293T cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with [l]{.smallcaps}-glutamine and 10% (*v*/*v*) bovine growth serum at 37 °C and 5% CO~2~. Cells grown to 60%--80% confluence (\~4 × 10^6^ per 100-mm dish) were transiently transfected for 24 h with mammalian expression vectors: pcDNA3.1 (empty vector), pcDNA3.1/Gα~q~, pcDNA3.1/Gα~11~, pcDNA3.1/Gα~q~ Q209E, pcDNA3.1/Gα~11~ Q209E, pcDNA3.1/Gα~q~ Q209L, or pcDNA3.1/Gα~11~ Q209L, using LipofectAMINE 2000 reagent (Invitrogen), according to the manufacturer's instructions, or using the CalPhos Mammalian Transfection protocol (Clonetech Laboratories, Takara Bio USA, Mountain View, CA, USA).

4.4. Cellular Fractionation {#sec4dot4-toxins-08-00233}
---------------------------

HEK-293T cells, transfected as described above, were treated with or without the indicated amounts of PMT for the indicated times, washed with 1× cold phosphate buffered saline, scraped and transferred into a microcentrifuge tube (Dot Scientific Inc., Burton, MI, USA), then lysed by 10 passages through a 27-gauge needle in 0.5 mL of an ice-cold lysis buffer A (50 mM Tris-HCl, pH 8.0, 2.5 mM MgCl~2~, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 1 mM dithiothreitol, and 10% glycerol) to generate whole cell lysates. Cellular fractionation was performed essentially, as described previously \[[@B50-toxins-08-00233]\]. In brief, nuclei were pelleted by centrifugation at 4 °C and 750× *g* for 5 min, and the post-nuclear supernatant was fractionated into membrane pellets and supernatants by centrifugation at 4 °C and 18,000× *g* for 30 min. The membrane pellets were resuspended in 0.5 mL of lysis buffer A. Membrane proteins were quantified using the Bio-Rad protein assay. Samples containing 10 µg of total membrane proteins were resolved by SDS-PAGE and analyzed by immunoblotting, as described below.

4.5. Immunoblotting Analysis {#sec4dot5-toxins-08-00233}
----------------------------

Proteins in samples were separated by 10% SDS-PAGE and transferred onto nitrocellulose membranes, and the membranes were immunoblotted with the indicated primary antibody overnight at 4 °C, washed, then incubated with the appropriate horseradish peroxidase-conjugated secondary antibody. After washing, immunoreactive proteins were visualized by using enhanced chemiluminescence (Pierce Biotechnology, Thermo Fisher Scientific, Grand Island, NY, USA) and captured on autoradiographic film. Image analysis and quantification of protein bands was performed using NIH ImageJ (version 1.48u4, NIH, Bethesda, MD, USA) and Microsoft Excel software (Microsoft Office Professional Plus 2013).

4.6. OptiPrep or Sucrose Density Gradient Subcellular Fractionation {#sec4dot6-toxins-08-00233}
-------------------------------------------------------------------

DRMs were prepared by density gradient centrifugation with OptiPrep or sucrose, as indicated, using a modification of previously described methods \[[@B38-toxins-08-00233],[@B43-toxins-08-00233]\]. All procedures were carried out on ice. Briefly, four 100-mm culture dishes of subconfluent HEK-293T cells were treated with rPMT at the indicated concentrations for the indicated times. Cells were washed twice with modified Tyrode's solution (20 mM HEPES, pH 7.4, containing 137 mM NaCl, 2.7 mM KCl, 1.0 mM MgCl~2~, 0.18 mM CaCl~2~, and 5.6 mM glucose). Cells were collected and washed twice with the ice-cold Tyrode's solution, then centrifuged at 1000× *g* for 10 min. The pellet was solubilized in 1 mL of lysis buffer B (50 mM Tris-HCl, pH 7.4, containing 50 mM NaCl, 0.1% Triton X-100, 5 mM EDTA, 1.0 mM Na~3~VO~4~, 5.0 mM Na~4~P~2~O~7~, and protease inhibitor cocktail, comprised of 0.2 mM aminoethyl-benzene sulfonyl fluoride, 1 µg/mL aprotinin, 10 µM bestatin, 3 µM E-64, 10 µg/mL leupeptin, 2 µM pepstatin, and 50 µg/mL calpain inhibitor I). The cell were lysed via sonication, then incubated at 4 °C for 1 h with frequent agitation. Cell lysates (1 mL) were mixed with 3 mL of OptiPrep or sucrose solution (60% aqueous iodixanol or sucrose, respectively) in a 12-mL centrifuge tube, and the mixture was overlaid first with 4 mL of 35% OptiPrep/sucrose solution diluted in STE buffer (50 mM Tris-HCl, pH 7.6, containing 50 mM NaCl, 5 mM EDTA, and 1.0 mM Na~3~VO~4~,) and then 4 mL of 5% OptiPrep/sucrose solution. Ultracentrifugation was performed at 200,000× *g* and 4 °C for 20 h using a Beckman SW40Ti rotor (Beckman Coulter, Inc., Indianapolis, IN, USA) Fractions of 1.0 mL each were collected from the top of the gradient. Total protein content of each fraction was quantified using Bio-Rad protein assay. The distribution of various proteins in the fractions was assessed by SDS-PAGE and immunoblotting, as described above.

4.7. Data Analysis {#sec4dot7-toxins-08-00233}
------------------

All data are presented as the mean ± standard deviation (SD) from at least three independent experiments, or as indicated. The *p* values were determined using the unpaired two-tailed Student's *t*-test. For [Figure 4](#toxins-08-00233-f004){ref-type="fig"}, [Figure 5](#toxins-08-00233-f005){ref-type="fig"} and [Figure 6](#toxins-08-00233-f006){ref-type="fig"}, two-way ANOVA was also performed using data analysis tools in Microsoft Excel (Microsoft Office Professional Plus 2013) for the curves of control (no toxin treatment) vs. PMT-treated cells over the time course from 0 to 6 h. Statistical significance was set at the 95% confidence level.

This work was supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases NIH/NIAID grant R01-AI038395 (to Brenda A. Wilson) and graduate fellowships from NIH/NIAID Infection Biology Training Program grant T32-AI078876 and University of Illinois at Urbana-Champaign UIUC Graduate College (to Nathan C. Clemons). We are grateful to Ankita Puri-Tanejah for construction of the FLAG-Gα11 plasmid.

B.A.W. and M.H. conceived and designed the experiments; N.C.C. and S.L. performed the experiments; N.C.C., S.L., M.H., and B.A.W. analyzed the data; B.A.W. and M.H. contributed reagents/materials/support; and B.A.W., N.C.C., and M.H. wrote the paper.

The authors declare no conflict of interest.

The following abbreviations are used in this manuscript: DMEMDulbecco's Modified Eagle's MediumDRMDetergent resistant membraneEDTAEthylenediaminetetraacetic acidEVEmpty vectorGPCRG-protein coupled receptorNTNo transfection and/or treatmentPLCβ1Phospholipase C β-1PMT*Pasteurella multocida* toxinSDStandard deviationSDS-PAGESodium dodecyl sulfate polyacrylamide gel electrophoresis

![Effect of *Pasteurella* *multocida* toxin (PMT) on the morphology of HEK-293T cells. Shown are representative phase-contrast micrographs of HEK-293T cells treated overnight with varying concentrations of PMT: (**a**) no toxin; (**b**) 0.01 nM; (**c**) 0.07 nM; (**d**) 0.65 nM; (**e**) 1.6 nM; and (**f**) 3.2 nM. Bar, 10 µm.](toxins-08-00233-g001){#toxins-08-00233-f001}

![PMT-mediated downregulation of endogenous Gα~q/11~ levels in detergent resistant membranes (DRMs). HEK-293T cells were incubated without or with 0.3 nM PMT for 10 h. Preparation of cell lysates and fractionation by OptiPrep density gradient centrifugation was performed, as described in Methods Section. Each sample was separated into 121-mL fractions from low density (top, fraction \#1) to high density (bottom, fraction \#12), with fraction \#5 containing the DRMs, as evidenced by the presence of the DRM-specific marker flotillin-1. The proteins were resolved by 10% SDS-PAGE gel and subsequently analyzed by immunoblotting using antibodies against Gα~q/11~, Gα~s~, Gβ, and flotillin-1 present in the cell lysates (Lys) and fractions \#4--12 from the density gradient.](toxins-08-00233-g002){#toxins-08-00233-f002}

![Time course and dose--response of PMT-mediated downregulation of endogenous Gα~q/11~ levels in detergent resistant membranes (DRMs). (**a**) Time course of PMT-mediated downregulation of Gα~q/11~ levels in DRMs. HEK-293T cells were incubated with 0.3 nM PMT for the indicated times. (**b**) Dose--response of PMT-mediated downregulation of Gα~q/11~ levels in DRMs. HEK-293T cells were incubated with the indicated concentrations of PMT for 10 h. Shown are representative immunoblots of the lysates and the DRM-containing fraction \#5 of the density gradients, prepared, separated by density gradient fractionation, and analyzed by immunoblotting, as described in [Figure 2](#toxins-08-00233-f002){ref-type="fig"}. Shown below the immunoblots are the corresponding plots of the quantification of the protein bands, where the data are presented as the mean ± SD of the relative ratio of the intensity of the Gα~q/11~ or Gβ bands to the corresponding flotillin-1 bands. Filled bars: Relative ratio of Gα~q/11~/flotillin-1. Open bars: Relative ratio of Gβ/flotillin-1. \* *p* \< 0.01; \*\* *p* \< 0.001, PMT treatment vs. no treatment for each blot (unpaired two-tailed Student's *t*-test). All data are from three or more independent experiments.](toxins-08-00233-g003){#toxins-08-00233-f003}

###### 

PMT-mediated downregulation of Gα~q~ and Gα~11~ levels in detergent resistant membranes (DRMs) from HEK-293T cells overexpressing Gα~q~ or Gα~11~. (**a**) Shown is a representative immunoblot of whole cell membranes from HEK-293T cells transfected for 24 h with either no transfection (NT), pcDNA3.1/Gα~q~, pcDNA3.1/Gα~11~, or empty vector pcDNA3.1 (EV). The proteins were resolved by 10% SDS-PAGE gel and subsequently analyzed by immunoblotting using antibodies against Gα~q/11~ and Gβ. (**b**) Time course of PMT-treated HEK-293T cells overexpressing Gα~q~. (**c**) Time course of PMT-treated HEK-293T cells overexpressing Gα~11~. Shown are representative immunoblots (bottom panels) and the corresponding quantification plots (top panels) of DRMs, prepared using sucrose density gradient fractionation as described in Methods, and analyzed as described in [Figure 2](#toxins-08-00233-f002){ref-type="fig"}. Cells overexpressing Gα~q~ or Gα~11~ were treated without PMT (left panel) or with 1.2 nM PMT (right panel) for the indicated times. Proteins in the DRM-containing fraction \#5 of the density gradient were resolved by 10% SDS-PAGE gel and analyzed by immunoblotting using antibodies against Gα~q/11~ or Gβ. Plotted data are presented as the mean ± SD. Filled bars: relative ratio of Gα~q/11~/Gβ. *N* is the number of independent experiments performed. \* *p* \< 0.05, PMT treatment vs. time 0 h for each blot.

![](toxins-08-00233-g004a)

![](toxins-08-00233-g004b)

###### 

PMT-mediated downregulation of Gα~q~ and Gα~11~ levels in membrane preparations from HEK-293T cells overexpressing Gα~q~ or Gα~11~. (**a**) Dose course of PMT-mediated downregulation of Gα~q~ levels in membrane preparations from HEK-293T cells overexpressing Gα~q~ treated with the indicated dosages of PMT for 3 h. (**b**) Time course of PMT-mediated downregulation of Gα~q~ levels in membrane preparations from HEK-293T cells overexpressing Gα~q~ treated without PMT (left panels) or with 1.2 nM PMT (right panels) for the indicated times. (**c**) Time course of PMT-mediated downregulation of Gα~11~ levels in whole membrane preparations from HEK-293T cells overexpressing Gα~11~ treated without or with PMT, as in (**b**). Shown are representative immunoblots (bottom panels) and the corresponding quantification plots (top panels) of whole cell membranes, prepared and analyzed as described in the Methods Section. The proteins in the membrane fractions were resolved by 10% SDS-PAGE gel and subsequently analyzed by immunoblotting using antibodies against Gα~q/11~ and Gβ. Filled bars: Relative ratio of Gα~q/11~/Gβ. *N* is the number of independent experiments performed. \* *p* \< 0.05, \*\* *p* \< 0.01, PMT treatment vs. time 0 h or dose 0 for each blot.

![](toxins-08-00233-g005a)

![](toxins-08-00233-g005b)

![PMT-mediated downregulation of FLAG-Gα~q~ and FLAG-Gα~11~ protein levels in detergent resistant membranes (DRMs) from HEK-293T cells overexpressing FLAG-Gα~q~ or FLAG-Gα~11~. (**a**) Dose-response of PMT-treated HEK-293T cells overexpressing FLAG-Gα~q~ were treated with the indicated dosages of PMT for 3 h. (**b**) Time course of PMT-treated HEK-293T cells overexpressing FLAG-Gα~q~ were treated without (left panel) or with 1.2 nM PMT (right panel) for the indicated times. (**c**) Time course of PMT-treated HEK-293T cells overexpressing FLAG-Gα~11~ treated with PMT, as in (**b**). Shown are representative immunoblots (bottom panels) and the corresponding quantification plots (top panels) of DRMs, prepared using OptiPrep density gradient fractionation and analyzed as described in [Figure 2](#toxins-08-00233-f002){ref-type="fig"}. Proteins in the DRM-containing fraction \#5 of the density gradient were resolved by 10% SDS-PAGE gel and analyzed by immunoblotting using antibodies against the FLAG-tag or Gβ. Plotted data are presented as the mean ± SD. Filled bars: Relative ratio of FLAG/Gβ. *N* is the number of independent experiments performed. \* *p* \< 0.05, \*\* *p* \< 0.01, PMT treatment vs. time 0 h or dose 0 for each blot.](toxins-08-00233-g006){#toxins-08-00233-f006}

![Dependence of PMT-mediated downregulation of membrane levels of Gα~q~ protein on the catalytic activity of PMT. HEK-293T cells overexpressing Gα~q~ (left panels) or Gα~11~ (right panels) were treated for 2 h without or with 1.2 nM PMT or the catalytically inactive mutant PMT C1165S. Shown are representative immunoblots (bottom panels) and the corresponding quantification plots (top panels) of whole cell membranes, prepared and analyzed as described in [Figure 3](#toxins-08-00233-f003){ref-type="fig"}. The proteins in the membrane fractions were resolved by 10% SDS-PAGE gel and subsequently analyzed by immunoblotting using antibodies against Gα~q/11~ or Gβ. Plotted data are presented as the mean ± SD. Filled bars: relative ratio of Gα~q/11~/Gβ. *N* is the number of independent experiments performed. \*\* *p* \< 0.01, PMT treatment vs. no treatment for each blot.](toxins-08-00233-g007){#toxins-08-00233-f007}

![Morphology of HEK-293T cells exogenously expressing constitutively active Gα-proteins and the effect of PMT on membrane levels of constitutively active Gα~q~ proteins. (**a**) Representative immunoblots of membrane preparations of HEK-293T cells overexpressing Gα~q~, Gα~11~, or their constitutively active Q209E and Q209L counterparts, using antibodies against Gα~q/11~ or Gβ. Control membranes were from cells transfected with empty vector pcDNA3.1 (EV). (**b**) Shown are phase-contrast micrographs of HEK-293T cells overexpressing the indicated Gα-protein, or without or with 1.2 nM PMT treatment, as indicated. NT, no transfection or treatment. Bar, 200 µm. (**c**) Representative immunoblots of membrane preparations showing protein levels of Gα~q~ Q209E, Gα~q~ Q209L, or Gβ in cells without or with 1.2 nM PMT treatment for 3 h PMT. Shown above the immunoblots are the corresponding plots of the quantification of the bands, where data are presented as the mean ± SD of the relative ratios of Gα~q/11~/Gβ. *N* is number of independent experiments performed. *p* \> 0.6, PMT treatment vs. no treatment for each plot.](toxins-08-00233-g008){#toxins-08-00233-f008}
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